blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3129401

EP3129401 - SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.04.2020
Database last updated on 15.08.2024
FormerThe patent has been granted
Status updated on  10.05.2019
FormerGrant of patent is intended
Status updated on  04.05.2019
FormerExamination is in progress
Status updated on  09.04.2019
FormerGrant of patent is intended
Status updated on  06.12.2018
FormerExamination is in progress
Status updated on  15.09.2017
FormerRequest for examination was made
Status updated on  13.01.2017
FormerThe international publication has been made
Status updated on  09.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2017/07]
Inventor(s)01 / MITCHELL, Tracy, S.
100 Beaver Street
Waltham, MA 02453 / US
02 / GOSSELIN, Michael, L.
100 Beaver Street
Waltham, MA 02453 / US
03 / LIPOVSEK, Dasa
100 Beaver Street
Waltham, MA 02453 / US
04 / PARKER, Rex
147 Church Road
Titusville, NJ 08560 / US
05 / CAMPHAUSEN, Ray
100 Beaver Street
Waltham, MA 02453 / US
06 / DAVIS, Jonathan
100 Beaver Street
Waltham, MA 02453 / US
07 / FABRIZIO, David
79 Lincoln Avenue
South Hamilton, MA 01982 / US
 [2017/07]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2017/07]Reitstötter Kinzebach
Patentanwälte
Sternwartstrasse 4
81679 München / DE
Application number, filing date15714135.919.03.2015
[2017/07]
WO2015US21535
Priority number, dateUS201461968181P20.03.2014         Original published format: US 201461968181 P
[2017/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015143199
Date:24.09.2015
Language:EN
[2015/38]
Type: A1 Application with search report 
No.:EP3129401
Date:15.02.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 24.09.2015 takes the place of the publication of the European patent application.
[2017/07]
Type: B1 Patent specification 
No.:EP3129401
Date:12.06.2019
Language:EN
[2019/24]
Search report(s)International search report - published on:EP24.09.2015
ClassificationIPC:C07K14/765, A61K38/39, A61K47/50, C07K14/78, C12N15/62
[2017/07]
CPC:
C07K14/78 (EP,CN,EA,IL,KR,US); A61K38/39 (EA,IL); A61K38/00 (EP,CN,EA,IL,KR,US);
A61K47/64 (EP,EA,IL,KR,US); C07K14/765 (IL); C12N15/62 (EA,IL);
C07K2319/00 (EP,CN,EA,IL,US); C07K2319/70 (EP,CN,EA,IL,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/07]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:SERUMALBUMINBINDENDE FIBRONECTIN-TYP-III-DOMÄNEN[2017/07]
English:SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS[2017/07]
French:DOMAINES DE FIBRONECTINE DE TYPE III SE LIANT À L'ALBUMINE SÉRIQUE[2017/07]
Entry into regional phase07.10.2016National basic fee paid 
07.10.2016Designation fee(s) paid 
07.10.2016Examination fee paid 
Examination procedure07.10.2016Examination requested  [2017/07]
07.10.2016Date on which the examining division has become responsible
04.05.2017Amendment by applicant (claims and/or description)
13.09.2017Despatch of a communication from the examining division (Time limit: M04)
22.01.2018Reply to a communication from the examining division
16.03.2018Despatch of a communication from the examining division (Time limit: M04)
25.07.2018Reply to a communication from the examining division
07.12.2018Communication of intention to grant the patent
04.04.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.04.2019Fee for grant paid
04.04.2019Fee for publishing/printing paid
03.05.2019Information about intention to grant a patent
03.05.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19170042.6  / EP3572424
Opposition(s)13.03.2020No opposition filed within time limit [2020/21]
Fees paidRenewal fee
10.03.2017Renewal fee patent year 03
13.03.2018Renewal fee patent year 04
13.03.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.03.2015
AL12.06.2019
AT12.06.2019
CY12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
MK12.06.2019
MT12.06.2019
NL12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
[2022/32]
Former [2022/28]HU19.03.2015
AL12.06.2019
AT12.06.2019
CY12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
MT12.06.2019
NL12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/50]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
NL12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/36]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/24]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
PT14.10.2019
IS24.02.2020
Former [2020/22]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/17]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/14]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
SM12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/12]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/11]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
PT14.10.2019
Former [2020/10]AL12.06.2019
AT12.06.2019
CZ12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
PT14.10.2019
Former [2020/09]AL12.06.2019
CZ12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
RS12.06.2019
SE12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
Former [2020/07]AL12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
NL12.06.2019
RS12.06.2019
SE12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
Former [2019/51]AL12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RS12.06.2019
SE12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
Former [2019/50]AL12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RS12.06.2019
SE12.06.2019
NO12.09.2019
GR13.09.2019
Former [2019/49]AL12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
SE12.06.2019
NO12.09.2019
Former [2019/48]FI12.06.2019
LT12.06.2019
SE12.06.2019
NO12.09.2019
Former [2019/47]FI12.06.2019
LT12.06.2019
NO12.09.2019
Cited inInternational search[A]WO2008096158  (DOMANTIS LTD [GB], et al) [A] 1-20 * the whole document *;
 [A]WO2009083804  (NOVARTIS AG [CH], et al) [A] 1-20 * the whole document *;
 [XI]WO2009133208  (NOVARTIS AG [CH], et al) [X] 1-3,7-11,15,16,18-20 * the whole document * * pages 12,14,19; figures 7,9,13,14; example -; claim -; sequences 1-3 * [I] 1-20;
 [XI]WO2011103105  (BRISTOL MYERS SQUIBB CO [US], et al) [X] 1-4,9-11,15,16,18-20 * the whole document * * paragraphs [[20]] - [[26]] - [[115]] - [[123]] - [[197]]; example -; claim -; sequence - * [I] 1-20;
 [XI]WO2011130354  (BRISTOL MYERS SQUIBB CO [US], et al) [X] 1-4,9-13,15-20 * paragraphs [0002] , [00 7] - [0014] - [0 37] - [42 67] - [0074] - [0 83] - [0117] - [ 170] - [0191]; example -; sequence 327 * * paragraphs [[0030]] , [[0031]] , [ [0038]] - [[0040]] - [[0176]] , [ [0241]]; example 5F; claim - * * the whole document * [I] 1-20;
 [XI]WO2011140086  (BRISTOL MYERS SQUIBB CO [US], et al) [X] 1-4,7,9-11,15,16,18-20 * the whole document * * claim 46 * * example -; claim - * * page 79; sequence 1 * [I] 1-20;
 [XP]WO2014165093  (BRISTOL MYERS SQUIBB CO [US]) [XP] 1-4,9-12,15,16,18-20 * the whole document * * examples 1-3; claim -; sequence 154 *;
 [XI]  - PETER-CHRISTIAN KLÖHN ET AL, "IBC's 23nd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA", MABS, (20130301), vol. 5, no. 2, doi:10.4161/mabs.23655, ISSN 1942-0862, pages 178 - 201, XP055137110 [X] 1-4,9-11,15,16,18-20 * page 194, column R * [I] 1-20

DOI:   http://dx.doi.org/10.4161/mabs.23655
 [A]  - LIPOVSEK D, "Adnectins: engineered target-binding protein therapeutics", PROTEIN ENGINEERING, DESIGN AND SELECTION, OXFORD JOURNAL, LONDON, GB, vol. 24, no. 1-2, Sp. Iss. SI, doi:DOI:10.1093/PROTEIN/GZQ097, ISSN 1741-0126, (20101110), pages 3 - 9, XP008153459 [A] 1-20 * the whole document *

DOI:   http://dx.doi.org/
 [A]  - SLEEP DARRELL ET AL, "Albumin as a versatile platform for drug half-life extension", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - GENERAL SUBJECTS, (20130429), vol. 1830, no. 12, doi:10.1016/J.BBAGEN.2013.04.023, ISSN 0304-4165, pages 5526 - 5534, XP028740219 [A] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bbagen.2013.04.023
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.